A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Conditions:   Idiopathic Pulmonary Fibrosis;   Systemic Sclerosis With Lung Involvement Interventions:   Drug: Vixarelimab;   Drug: Placebo Sponsor:   Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials